The high expression of LEF1-AS1 is associated with the low survival rate of patients with cancers such as glioma, osteosarcoma, lung cancer, ovarian cancer, colorectal cancer, esophageal squamous cell carcinoma, etc., suggesting that LEF1-AS1 can be used as a biomarker for early detection and prognostic evaluation. This evidence concerns the gene LEF1 and ovarian carcinoma.